Report Highlights

The United States' Role in the Global Pericarditis Therapeutics Supply Chain

The United States sits at the demand and finishing end of the pericarditis therapeutics chain rather than the upstream synthesis end. Domestic production concentrates in oral generic colchicine tablets finished at plants in New Jersey and Pennsylvania, while colchicine active ingredient arrives mainly from China and India through ocean freight into the Port of Newark and the Port of Los Angeles. Import dependency at the API layer is effectively total.

Value capture sits with the biologic and branded segment. Regeneron manufactures rilonacept in New York State, and finished vials move through refrigerated distribution to hospital and specialty pharmacies nationwide. Anakinra, supplied by Sobi through European lines, serves off-label use, so the strategic vulnerability lies in generic colchicine volume rather than biologic output.

Growth Drivers for Pericarditis Therapy Trade and Production in the United States

Recurrence is the primary volume driver. Each recurrent episode extends colchicine courses to three to six months, which lifts annual API throughput per patient and pushes domestic tablet finishers to add line capacity. Cardiology practices across the Northeast and Midwest are the main sources of this incremental prescription demand.

Second, biologic lifecycle expansion is shifting cold-chain logistics. Rilonacept requires refrigerated handling from manufacturing through last-mile delivery, which is expanding specialty pharmacy distribution hubs. Third, the August 2025 executive order establishing a Strategic Active Pharmaceutical Ingredients Reserve is pushing import substitution toward domestic API intermediates.

Supply Chain Risks and Trade Barriers

API concentration represents the most severe supply risk. Colchicine synthesis at a small number of Chinese and Indian facilities means that a single FDA warning letter or unannounced inspection can remove a meaningful share of U.S. generic supply within weeks. Finished-dose manufacturers carry limited safety stock, so shortages propagate quickly to retail and hospital pharmacies.

Trade exposure compounds this risk. Section 301 tariffs on Chinese-origin goods raise landed API costs for certain intermediates, while rupee volatility affects the pricing of Indian supply contracts. Rilonacept's refrigerated requirements also expose the biologic channel to temperature excursions during air freight transfers and regional distribution.

Trade and Investment Opportunities in the United States

Domestic API onshoring presents the clearest opportunity. Investment in colchicine intermediate synthesis at existing sites in Ohio or Puerto Rico would reduce import dependency and qualify for federal supply chain incentives tied to the strategic reserve program. Contract manufacturers with sterile and oral solid capacity are well positioned to capture this demand.

Puerto Rico's pharmaceutical manufacturing zone offers a logistics hub opportunity for serving Latin American and Caribbean markets under existing trade arrangements. Specialty cold-chain distributors in the Northeast can also capture rilonacept volume by building regional refrigerated warehousing near Newark and Philadelphia.

Market at a Glance

Leading Market Participants

• Regeneron Pharmaceuticals
• Takeda Pharmaceutical
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Sobi
• Teva Pharmaceuticals
• Viatris
• Sun Pharmaceutical
• Zydus Pharmaceuticals
• Dr. Reddy's Laboratories

Regulatory and Trade Policy Environment

Pericarditis therapeutics fall under FDA oversight through the Hatch-Waxman framework for generics and biologics licensing for rilonacept and anakinra. Finished generic colchicine must meet current good manufacturing practice standards, and the Drug Supply Chain Security Act requires product tracing and serialization across every distribution step from manufacturer to dispensing pharmacy.

Tariff and trade rules shape import economics. Section 301 duties apply to Chinese-origin pharmaceutical inputs, while the USMCA governs certain trade flows from Canada and Mexico. Pharmaceutical imports from India enter under standard most-favored-nation duty treatment, and investment incentives for domestic API production are increasingly linked to federal strategic reserve policy.

U.S. Pericarditis Therapeutics Supply Chain Outlook to 2032

Through 2032, the supply chain will shift from import-dependent generic finishing toward partially domestic API production. Expanded colchicine intermediate capacity in the United States would reduce exposure to single-country inspection risk and shorten lead times for hospital procurement contracts.

Comparative advantage will move toward cold-chain biologic distribution as rilonacept and related interleukin-1 blockers expand into broader indications. Specialty logistics networks in the Northeast and Puerto Rico will capture a growing share of value as refrigerated handling becomes the decisive capability in this market.